Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1128

Sort by

Sort Order Select

Journal Articles

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party

Blood blood.2025031480.

https://doi.org/10.1182/blood.2025031480

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia

Roberta S. Azevedo, Elias Jabbour, Hagop M Kantarjian, Sravanthi Lavu, Sanam Loghavi, Nitin Jain, Koji Sasaki, Rebecca Garris, Koichi Takahashi, Farhad Ravandi, Nicholas J. Short

Blood blood.2025030498.

https://doi.org/10.1182/blood.2025030498

Published: 2025

Includes: Supplemental data

Journal Articles

Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

Blood blood.2024027948.

https://doi.org/10.1182/blood.2024027948

Published: 2025

Includes: Supplemental data

Journal Articles

Consolidation with CAR T-cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab

Hannah Goulart, Elias Jabbour, Nitin Jain, Farhad Ravandi, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Alex Bataller, Fadi Haddad, Rita Khouri, Jayastu Senapati, Rebecca Garris, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 3350.

https://doi.org/10.1182/blood-2025-3350

Published: 2025

Journal Articles

Inotuzumab ozogamicin leads to high rates of measurable residual disease negativity for patients with B-cell acute lymphoblastic leukemia in morphologic remission

Hannah Goulart, Elias Jabbour, Nitin Jain, Fadi Haddad, Jayastu Senapati, Rita Khouri, Guillermo Garcia-Manero, William Wierda, Farhad Ravandi, Naveen Pemmaraju, Kelly Chien, Rebecca Garris, Nicholas Short, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 3348.

https://doi.org/10.1182/blood-2025-3348

Published: 2025

Journal Articles

Acute Myeloid Leukemia with deletion 12p: An adverse-risk disease

William D. Marrero, Mina Abdelmalek, Farah Al Haj, Tapan Kadia, Courtney DiNardo, Elias Jabbour, Sanam Loghavi, Gautam Borthakur, Nicholas Short, Ghayas Issa, Jayastu Senapati, Wei-Ying Jen, Naveen Pemmaraju, Fnu Amritpal Singh, Abhishek Maiti, Guillermo Garcia-Manero, Farhad Ravandi, Naval Daver

Blood (2025) 146 (Supplement 1): 5179.

https://doi.org/10.1182/blood-2025-5179

Published: 2025

Journal Articles

A blood-based protein signature adds to genomic prognostication of survival in TP53-mutated Acute Myeloid Leukemia

Sara Nofal, Jennifer Marvin-Peek, Sanam Loghavi, Jayastu Senapati, Bofei Wang, Fadi Haddad, Nicholas Short, Naval Daver, Ghayas Issa, Koji Sasaki, Gautam Borthakur, Tapan Kadia, Courtney DiNardo, Farhad Ravandi, Guillermo Garcia-Manero, Ehsan Irajizad, Hussein Abbas

Blood (2025) 146 (Supplement 1): 3503.

https://doi.org/10.1182/blood-2025-3503

Published: 2025

Journal Articles

Changing dogma regarding mutation primacy in acute myelogenous leukemia : Protein expression supersedes mutation status

Steven Kornblau, Eduardo de Camargo Magalhaes, Brandon Brown, Samanta Catueno, Yihua Qiu, Courtney DiNardo, Farhad Ravandi

Blood (2025) 146 (Supplement 1): 3492.

https://doi.org/10.1182/blood-2025-3492

Published: 2025

Journal Articles

Blinatumomab and ponatinib vs. hyper-CVAD and ponatinib in patients with Philadelphia-chromosome positive acute lymphoblastic leukemia: A propensity score analysis

Koji Sasaki, Hagop Kantarjian, Nicholas Short, Nitin Jain, Xuelin Huang, Farhad Ravandi, William Wierda, Gautam Borthakur, Ghayas Issa, Yesid Alvarado Valero, Naveen Pemmaraju, Guillermo Garcia-Manero, Rebecca Garris, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1578.

https://doi.org/10.1182/blood-2025-1578

Published: 2025

Journal Articles

Updated results of A phase II study of blinatumomab in adults with measurable residual disease of 10-4 or higher

Caitlin Rausch, Hagop Kantarjian, Nitin Jain, Jeffrey Jorgensen, Sa Wang, Xuemei Wang, Maro Ohanian, Yesid Alvarado Valero, Tapan Kadia, Koji Sasaki, Rebecca Garris, Guillermo Garcia-Manero, Farhad Ravandi, Nicholas Short, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1575.

https://doi.org/10.1182/blood-2025-1575

Published: 2025

Journal Articles

Blinatumomab and ponatinib demonstrates ongoing efficacy as frontline therapy in Philadelphia positive B-cell acute lymphoblastic leukemia: Long-term follow-up from a phase 2 Study

Hannah Goulart, Elias Jabbour, Nitin Jain, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Kelly Chien, Fadi Haddad, Jayastu Senapati, Rita Khouri, Farhad Ravandi, Guillermo Garcia-Manero, Rebecca Garris, Nicholas Short, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 1571.

https://doi.org/10.1182/blood-2025-1571

Published: 2025

Journal Articles

The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study

Hannah Goulart, Hagop Kantarjian, Nitin Jain, Rita Khouri, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Alessandra Ferrajoli, Alex Bataller, Fadi Haddad, Jayastu Senapati, Guillermo Garcia-Manero, Rebecca Garris, Farhad Ravandi, Nicholas Short, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1567.

https://doi.org/10.1182/blood-2025-1567

Published: 2025

Journal Articles

Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis

Hannah Goulart, Hagop Kantarjian, Koji Sasaki, Nitin Jain, Caitlin Rausch, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Farhad Ravandi, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Danielle Hammond, Mahesh Swaminathan, Rita Khouri, Maro Ohanian, Rebecca Garris, Nicholas Short, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1566.

https://doi.org/10.1182/blood-2025-1566

Published: 2025

Journal Articles

Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 1556.

https://doi.org/10.1182/blood-2025-1556

Published: 2025

Journal Articles

Impact of uncontrolled hyperglycemia during induction chemotherapy on response and survival outcomes in patients with adult B-cell acute lymphoblastic leukemia (B-ALL) on HCVAD-based regimens

Grace Park, Hagop Kantarjian, Nicholas Short, Nitin Jain, Farhad Ravandi, Kelly Chien, Jayastu Senapati, Fadi Haddad, Rita Khouri, Tapan Kadia, Naval Daver, Courtney DiNardo, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Naveen Pemmaraju, Rebecca Garris, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1544.

https://doi.org/10.1182/blood-2025-1544

Published: 2025

Journal Articles

Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 2075.

https://doi.org/10.1182/blood-2025-2075

Published: 2025

Journal Articles

Radiotherapy of extramedullary acute myeloid leukemias overcomes resistance to checkpoint blockade that is enhanced by natural killer cell depletion

Francisco Rodolfo Saenz, Bouthaina Dabaja, Naval Daver, Farhad Ravandi, Susan Wu, Timothy Lin, Penny Fang, Jillian Gunther, Tapan Kadia, Gautam Borthakur, William Wierda, Elias Jabbour, Naveen Pemmaraju, Chelsea Pinnix, Hagop Kantarjian, Nitin Jain, Michael Spiotto

Blood (2025) 146 (Supplement 1): 1727.

https://doi.org/10.1182/blood-2025-1727

Published: 2025

Journal Articles

Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML)

Blood (2025) 146 (Supplement 1): 1726.

https://doi.org/10.1182/blood-2025-1726

Published: 2025

Journal Articles

Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial

Jayastu Senapati, Hagop Kantarjian, Tapan Kadia, Naveen Pemmaraju, Courtney DiNardo, Naval Daver, Andres Quesada, Austin Wilson, Kayla Farish, Fadi Haddad, Farhad Ravandi, Guillermo Garcia-Manero, Gautam Borthakur

Blood (2025) 146 (Supplement 1): 1724.

https://doi.org/10.1182/blood-2025-1724

Published: 2025

Journal Articles

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Blood (2025) 146 (Supplement 1): 5647.

https://doi.org/10.1182/blood-2025-5647

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party

Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia

Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

Consolidation with CAR T-cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab

Inotuzumab ozogamicin leads to high rates of measurable residual disease negativity for patients with B-cell acute lymphoblastic leukemia in morphologic remission

Acute Myeloid Leukemia with deletion 12p: An adverse-risk disease

A blood-based protein signature adds to genomic prognostication of survival in TP53-mutated Acute Myeloid Leukemia

Changing dogma regarding mutation primacy in acute myelogenous leukemia : Protein expression supersedes mutation status

Blinatumomab and ponatinib vs. hyper-CVAD and ponatinib in patients with Philadelphia-chromosome positive acute lymphoblastic leukemia: A propensity score analysis

Updated results of A phase II study of blinatumomab in adults with measurable residual disease of 10-4 or higher

Blinatumomab and ponatinib demonstrates ongoing efficacy as frontline therapy in Philadelphia positive B-cell acute lymphoblastic leukemia: Long-term follow-up from a phase 2 Study

The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study

Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis

Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia

Impact of uncontrolled hyperglycemia during induction chemotherapy on response and survival outcomes in patients with adult B-cell acute lymphoblastic leukemia (B-ALL) on HCVAD-based regimens

Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes

Radiotherapy of extramedullary acute myeloid leukemias overcomes resistance to checkpoint blockade that is enhanced by natural killer cell depletion

Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML)

Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only